VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

As the FDA opens the door to non-animal safety testing, VivoSim’s human-relevant models are already helping lower drug costs SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today celebrated the U.S. […]